৳ 750/unit
Pack: ৳ 750
৳ 750/unit
Pack: ৳ 750
At a glance
Irreversible ErbB family blocker and tyrosine kinase inhibitor used in EGFR mutation-positive metastatic NSCLC.
Indications
First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) possessing non-resistant EGFR mutations (Exon 19 deletions or Exon 21 L858R substitutions), and previously treated metastatic squamous NSCLC progressing after platinum-based chemotherapy.
Pharmacology
Afatinib covalently binds to EGFR, HER2, and HER4, irreversibly inhibiting tyrosine kinase autophosphorylation and downregulating ErbB signaling in cancer cells.
Dosage
Recommended dose: 40 mg orally once daily. Severe renal impairment (eGFR 15 to 29 mL/min/1.73 m²): 30 mg orally once daily.
Side effects
Common to severe: Diarrhea, bullous/exfoliative skin disorders, rash, paronychia, stomatitis, decreased appetite, keratitis, elevated liver enzymes, and interstitial lung disease (ILD).
Use in pregnancy
Pregnancy Category D. Can cause fetal harm when administered to a pregnant woman. Females of reproductive potential must use effective contraception.
Pregnancy Category: D — always consult a doctor before taking during pregnancy.
Precautions & warnings
Withhold or reduce dose for severe or prolonged Grade ≥2 diarrhea, cutaneous reactions, suspected interstitial lung disease (ILD), hepatic toxicity, or keratitis.
Overdose effects
Overdose can lead to nausea, vomiting, asthenia, dizziness, headache, abdominal pain, and elevated amylase levels. Supportive management is indicated.
Storage conditions
Store below 30°C in a dry and cool place, away from sunlight. Keep out of reach of children.